Posible Nueva Arma Para Tratar a Pacientes con Cáncer de Pulmón Microcítico ( Células Pequeñas ) .
- ASTRUM-005 is the First Study to Demonstrate that PD-1 Inhibitors plus Chemotherapy can improve Survival for Patients With ES-SCLC.
- In ASTRUM-005, SERPLULIMAB combined with Chemotherapy achieved by far the longest OS in First-line immunotherapy for ES-SCLC. Compared with chemotherapy, the Treatment prolonged median OS by 4.5 months and had the lowest HR of 0.63.
- HANSIZHUANG (SERPLULIMAB) is Expected to Become the world's First anti-PD-1 mAb for the First-line Treatment of SCLC and to fill the clinical gap in the next five years . ...